Diabetes, obesity, and cardiovascular disease are risk factors for mortality and morbidity. The number of people with diabetes is growing rapidly and it is now estimated that about 5% of the population of developed countries is afflicted.
1) Diabetes often leads to long-term complications such as neuropathy, nephropathy, retinopathy, cataract, and angiopathy. Among them, diabetic neuropathy is the most prevalent complication of diabetes mellitus in both type 1 and type 2 patients. The average prevalence of neuropathy in diabetic patients is estimated at 50% approximately.
2 ) The maintenance of blood glucose at an appropriate level is a good way to prevent diabetic complications, because there is a link between hyperglycemia and the development of the disease.
3) The practical control of blood glucose, however, has been difficult to achieve the normal level at present. Therefore, agents able to prevent or ameliorate diabetic complications without strict glycemic control are needed. While aldose reductase inhibitors, for example, have been extensively studied, 4, 5) they have had limited effects on the progression of neuropathy; or been withdrawn from the world markets excepting some countries because of adverse effects. Although positive symptoms such as pain can be treated with anticonvulsants or antidepressants, frequent side effects limit their usage for chronic pain.
The pathogenesis of diabetic neuropathy is still unclear though the disease is recognized to be multifactorial. There are many candidates of causative factor, including the activation of a polyol pathway, oxidative stress, insufficient blood supply to the nerves, autoimmune reactions, etc. 5) Among them, a lack of neurotrophic support has been focused on because of its importance for the nervous system. 6) Neurotrophic factors play pivotal roles in maintaining neural phenotypes and are already in clinical trials for the treatment of diseases of the peripheral nervous system. Neurotrophins, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) that are released from the neuron itself or its target tissues, 7) are a small gene family of structurally and functionally related neurotrophic factors. Among these neurotrophins, NGF has been tested the most extensively in animal models of diabetic neuropathy with encouraging results. [8] [9] [10] [11] Recombinant human nerve growth factor (rhNGF) was tested in clinical trials for the treatment of patients with diabetes. 12) However, it has not shown clear efficacy probably because of limited delivery to the nervous system. Based upon these facts, we hypothesized that one way to treat diabetic neuropathy would be to increase the endogenous production of neurotrophic factors.
In the previous paper, Meguro and his colleagues reported that five-membered heteroaryl alkanoic acid derivatives, especially w-oxazolylalkanoic acids (1), acted as antidiabetic agents promoting the glucose-dependent secretion of insulin (Chart 1). 13) We found that a series of 5-(w-aryloxyalkyl)oxazole derivatives (2, Chart 1), prepared in the course of studies on novel insulin secretagogues, increased the endogenous production of neurotrophic factors, especially BDNF, both in vitro and in vivo. It is well-known that BDNF supports the subsets of sensory neurons involved in mechanical pressure sensation and pain sensation. 14) Furthermore, BDNF promotes the survival of motorneurons, unlike NGF.
15) Therefore, compounds able to increase the endogenous production of BDNF might be clinically useful in the treatment of diabetic neuropathy.
We describe in this paper the syntheses and biological ef- 4 /ml of the cells were seeded into poly-lysine-coated 48-well dishes at 0.3 ml/well and incubated for 8 d.
Measurement of BDNF 17) in Culture Supernatant The growth medium was replaced with 0.2 ml of DMEM containing 1% (w/v) bovine serum albumin and incubated for another 2 d. The collected culture supernatants were kept at Ϫ80°C until the BDNF assay. Human BDNF was measured using an enzyme-linked immuno-sorbent assay system built up with commercial items. Briefly, monoclonal anti-human BDNF antibody (R&D, Minneapolis, MN, U.S.A.) was coated on immunoplates at 1 mg/ml, and blocked with a commercial buffer (Promega, Madison, WI, U.S.A.). The collected culture supernatants were directly applied onto the plates, which were incubated at room temperature for 2 h. After repeated washes, the plates were incubated with the secondary anti-BDNF antibody (Promega) and successively with HRP-conjugated anti-goat IgG antibody (Promega). Color development was achieved by adding substrate solution (TMB peroxidase EIA substrate kit, Bio-Rad, Richmond, CA, U.S.A.). The BDNF concentration was determined by measuring absorbance at 450 nm. The concentration required for a 50% increase, the EC 50 , was obtained from regression analysis.
In Vivo. Animals and Experimental Design Six-weekold male Sprague Dawley rats (Clea Japan, Inc., Tokyo, Japan) were intravenously injected with 70 mg/kg of streptozotocin (STZ) (Sigma, St. Louis, MO, U.S.A.). Three weeks later, they were divided into 3 groups so that mean body weights and blood glucose levels were similar among the groups. In the treatment group, 10 mg/kg/d of compound 13a suspended in 0.5% (w/v) methylcellulose at 5 ml/kg was orally administered for 4 weeks. For the untreated STZ-diabetic rats and normal rats, only 0.5% (w/v) methylcellulose was given.
Nerve Conduction Velocity At the end of the treatment oil -period, rats were anaesthetized with pentobarbital sodium (Dabbott laboratories) by intraperitoneal injection (50 mg/kg). Motor nerve conduction velocity was measured between sciatic notch and knee in the nerve branch to tibialis anterior muscle with Neuropack 2 (Nihon Kohden), which is representative of the whole sciatic nerve in terms of susceptibility to diabetes and treatment effects. Nerve temperature was monitored and regulated between 36.5 and 37.5°C. Tail Flick Response Each animal was gently held and its tail was exposed to the radiant heat of a specialized device to evoke a tail-flick response (Model 33, IITC Inc. Woodland Hills, CA, U.S.A.), and the latency until the tail flicked was automatically recorded.
Nerve BDNF Levels At the end of the experiment, the sciatic nerve was obtained and stored at Ϫ80°C until further analysis. The protein level of BDNF in the sciatic nerve was determined by enzyme-linked immunosorbent assay (ELISA) as reported previously (Inoue et al., 1997) . Briefly, the supernatants from sciatic nerve homogenates were applied onto immunoplates coated with anti-BDNF antibody. After incubation and washes, the plates were incubated with biotinylated anti-BDNF antibody. Then, streptavidin-conjugated bgalactosidase was added to the plates, to be followed by an enzymic reaction with the substrate, 4-methylumbelliferyl-b-D-galactosidase, and the measurement of fluorescence produced by excitation at 355 nm and emission at 460 nm. The nonspecific reaction was quantified from a paralleled reaction in non-coated wells and subtraction from the specific antibody-coated wells.
Results and Discussion
The effects on BDNF production of the novel 5-(w-aryloxyalkyl)oxazole derivatives described above are summarized in Table 3 . The 2-azolyloxazole derivatives 13a-g strongly promoted the production. The 2-methylimidazolyl (13a, EC 50 ϭ7.9 mM), imidazolyl (13b, EC 50 ϭ5.7 mM), pyrazolyl (13e, EC 50 ϭ6.5 mM), and benzimidazolyl (13g, EC 50 ϭ 5.1 mM) derivatives were also highly active. On the other hand, compound 13f with a 1,2,4-triazolyl group at the 2-position on the oxazole ring exhibited a slight loss of activity (EC 50 ϭ13.9 mM). With regard to the substituent of the imidazole ring at C2 on the oxazole ring, introduction of a relatively bulky group such as a 2-ethyl (13c, EC 50 ϭ9.8 mM) or a 2-propyl (13d, EC 50 ϭ9.7 mM) group resulted in a minor decrease in activity. It is worth noting that replacement of the C2 azolyl moiety by a phenyl group (13h) significantly reduced the BDNF level (EC 50 Ͼ50.0 mM). These findings indicated that an azolyl moiety of the proper size at the 2-position on the oxazole ring was necessary for a good effect on BDNF production by the 5-(w-aryloxyalkyl)oxazole series.
We next directed our attention to a substituent on the benzene ring, which was linked by an oxygen atom with the 5-alkylene chain of the oxazole ring. Compound 13m with a 2-methylthio moiety (EC 50 ϭ11.0 mM), which was very similar to a 2-methoxy group, showed less activity than compound 13a, whereas replacement of the 2-methoxy group of 13a by a 2-ethoxy group (13k, EC 50 ϭ6.5 mM) resulted in retention of activity. Furthermore, replacement of the methoxy group of 13a by a cyano (13n, EC 50 ϭ5.5 mM) and a methyl group (13o, EC 50 ϭ6.1 mM) slightly increased activity. Removal of the 2-methoxy group, however, resulted in a reduction of the BDNF content (13i, EC 50 ϭ13.1 mM). In addition, compound 13j replaced by a hydroxy group (EC 50 ϭ36.0 mM) was less active than compound 13a. Compounds with a relatively bulky group such as an iso-propoxy (13l, EC 50 ϭ9.4 mM) or an iso-propyl (13p, EC 50 Ͼ50.0 mM) group exhibited decreased activity. It is of note that the position of the substitution on the benzene ring greatly influenced potency. The para-isomer (13r, EC 50 ϭ6.7 mM) was as active as the corresponding ortho-isomer 13o, whereas the meta-analogue (13q, EC 50 ϭ10.3 mM) was about 1.7 times less active than 13o. In addition, compounds possessing two substituents such as 13s (EC 50 ϭ46.8 mM) or 13t (EC 50 ϭ14.8 mM) showed reduced activity compared with the corresponding monosubstituted derivative 13o. These results showed that a lipophilic substituent of the proper size, especially at the 2-position on the benzene ring, was required for an optimal effect on BDNF production by the 5-(w-aryloxyalkyl)oxazole derivatives. The length of the methylene chain between the oxazole ring and the phenoxy moiety was also investigated. Compound 13u (EC 50 ϭ29.8 mM) with a tetramethylene unit (mϭ4) was about 5-fold less active than compound 13o. As compounds 13v (mϭ5, EC 50 Ͼ50.0 mM) and 13w (mϭ6, EC 50 Ͼ50.0 mM) show, the activity reduced in accordance with prolonging length of the methylene chain between the oxazole ring and the phenoxy group.
Compound 13a, one of the most promising compounds, was examined for oral therapeutic effects on diabetic neuropathy in STZ-diabetic rats as a typical type 1 diabetic model. Furthermore, the tissue level of BDNF was evaluated after oral administration of 13a. As shown in Table 4 , the un-568
Vol. 51, No. 5 treated STZ-diabetic rats showed the significantly reduced motor nerve conduction velocity (MNCV). They also exhibited the impaired tail-flick response, which is one of the indicators of the function of sensory neurons. Treatment with 13a (10 mg/kg/d p.o., for 4 weeks) significantly improved both the MNCV and the tail-flick response without changing the plasma glucose level. The level of nerve BDNF declined in the untreated STZ-diabetic rats compared with normal rats, but administration of 13a significantly restored BDNF production.
In summary, we showed that a series of 5-(w-aryloxyalkyl)oxazole derivatives enhance BDNF production in human neuroblastoma cells. The results of the SAR studies identified that the azolyl moiety at the 2-position on the oxazole ring and the lipophilic substituent of the proper size, especially at the 2-position on the benzene ring connected with the propyloxy-spacer to the oxazole ring, were required for an optimal effect on BDNF production by the 5-(w-aryloxyalkyl)oxazole derivatives. Compound 13a, one of the most promising compounds, produced on improvement in both the MNCV and the tail-flick response accompanied by a recovery of the BDNF level in STZ-diabetic rats. These results suggest that 5-(w-aryloxyalkyl)oxazole derivatives might be clinically useful in the treatment of diabetic neuropathy. Further investigation of this series as a remedy for diabetic neuropathy is underway.
Experimental
All melting points were determined on a Yanagimoto micro melting point apparatus, and are uncorrected. Methyl 5-(4-Chlorophenyl)-5-oxo-4-(phenoxycarbonyloxy)pentanoate (5a, n‫)2؍‬ Bromine (51.1 g, 320 mmol) was added dropwise to a stirred solution of 4a (77.0 g, 320 mmol) in CH 2 Cl 2 (400 ml) at room temperature. The reaction mixture was washed successively with aqueous Na 2 SO 3 , saturated aqueous NaHCO 3 , and water. The organic layer was separated, dried A mixture of methyl 4-bromo-5-(4-chlorophenyl)-5-oxopentanoate (89.5 g, 280 mmol) and HCO 2 Na (76.2 g, 1.12 mol) in MeOH (400 ml) was refluxed for 12 h. After removal of the solvent, the residue was diluted with water and extracted with AcOEt. The organic layer was washed with water, dried (MgSO 4 ), and concentrated in vacuo to give an oil. The oil was dissolved in tetrahydrofuran (THF) (400 ml) and then pyridine (22.0 g, 278 mmol) was added. After addition of ClCO 2 Ph (43.8 g, 280 mmol) to the ice-cooled mixture, the resultant was stirred at room temperature for 1 h. The reaction mixture was poured into water and extracted with AcOEt. The organic layer was washed with brine, dried (MgSO 4 ), and concentrated in vacuo to give the title compound (5a, 61.2 g, 56%) as colorless crystals. mp 97-98°C (MeOH). Methyl 6-(4-Chlorophenyl)-6-oxo-5-(phenoxycarbonyloxy)hexanoate (5b, n‫)3؍‬ A mixture of methyl adipoyl chloride (3b, 17.9 g, 100 mmol), aluminum chloride (26.7 g, 200 mmol), and chlorobenzene (33.8 g, 300 mmol) was stirred at room temperature for 2 h, poured into 1 N HCl and extracted with AcOEt. The extract was washed with brine, dried (MgSO 4 ), and concentrated in vacuo to give colorless crystals. The crystals were dissolved in CH 2 Cl 2 (200 ml) and bromine (16.0 g, 100 mmol) was added dropwise to the solution at room temperature. The reaction mixture was washed successively with aqueous Na 2 SO 3 , saturated aqueous NaHCO 3 , and water. The organic layer was separated, dried (MgSO 4 ), and concentrated in vacuo to give methyl 5-bromo-6-(4-chlorophenyl)-6-oxohexanoate (31.7 g, 95%) as a colorless oil. A mixture of methyl 5-bromo-6-(4-chlorophenyl)-6-oxohexanoate (31.7 g, 95 mmol), HCO 2 Na (25.8 g, 379 mmol), and MeOH (150 ml) was refluxed for 12 h. After removal of the solvent, the residue was diluted with water and extracted with AcOEt. The organic layer was washed with brine, dried (MgSO 4 ), and concentrated in vacuo to give an oil. The oil was dissolved in THF (200 ml) and then pyridine (8.27 g, 105 mmol) was added. After addition of ClCO 2 Ph (16.4 g, 105 mmol) to the mixture with cooling, the resultant was stirred at room temperature for 1 h. The reaction mixture was poured into water and extracted with AcOEt. The extract was washed with brine, dried (MgSO 4 ), and concentrated in vacuo to leave an oil which was purified by column chromatography on SiO 2 (200 g) with AcOEt-hexane (1 : 4, v/v) to give the title compound (5b, 24.8 g, 63% yield from 3b) as a colorless oil. 1 
Methyl 3-[4-(4-Chlorophenyl)-2-oxo-2,3-dihydro-5-oxazolyl]propionate (6a, n‫)2؍‬
A mixture of 5a (61.2 g, 162 mmol), NH 4 OAc (62.6 g, 812 mmol), and AcOH (300 ml) was refluxed for 2 h. The reaction mixture was concentrated, and diluted with water to give the title compound (6a, 570
Vol. 51, No. 5 B. 3-[2-Chloro-4-(4-chlorophenyl)-5 oxazolyl]propionic Acid (10a, n‫)2؍‬ To an ice-cooled suspension of 7a (56.6 g, 189 mmol) in EtOH (300 ml) was added dropwise 1 N NaOH (226 ml). After stirring at room temperature for 1 h, the reaction mixture was poured into ice-water and acidified with 6 N HCl (40 ml) to give the title compound (10a, 51.6 g, 96%) as colorless crystals. mp 167-168°C (AcOEt). 
General Procedure for Method

3-[4-(4-Chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]-1-propanol (9a)
Lithium aluminum hydride (1.20 g, 31.6 mmol) was added portionwise to a stirred solution of 8a (10.8 g, 0.030 mol) in THF (120 ml) at 0°C. After stirring at the same temperature for 2 h, the reaction mixture was quenched with water (3 ml) and the insoluble material was removed by filtration. The filtrate was concentrated in vacuo to give colorless crystals. Recrystallization from acetone-isoPr 2 
4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)oxazole (13a)
A solution of diethyl azodicarboxylate in toluene (40%, 875 mg, 2.01 mmol) was added dropwise to a stirred solution of 9a (320 mg, 1.01 mmol), 2-methoxyphenol (250 mg, 2.01 mmol), and tributylphosphine (405 mg, 2.00 mmol) in THF (10 ml) at room temperature. After stirring for 4 h, the reaction mixture was concentrated in vacuo to give an oil which was purified by chromatography on SiO 2 (40 g). Elution with AcOEt-hexane (1 : 1, v/v) gave the title compound (13a, 230 mg, 54%) as colorless crystals. mp 84-85°C (Et 2 O-hexane). Compounds 13b, 13e, 13f, 13h, 13i , and 13k-w were obtained similarly. The yields, recrystallization solvents, and melting points were listed in Table 3 
